Bicistronic plasmids and NanoPlasmid™ technology streamline 4-1BBL/IL-12 delivery for tumor immune reprogramming

Effective tumor immune reprogramming relies on delivering immunomodulatory agents like 4-1BB ligand (4-1BBL) and interleukin 12 (IL-12) to transform tumor cells into tumor-associated antigen-presenting cells (tAPCs). Current approaches often use dual-plasmid systems delivered via poly(β-amino ester) (PBAE) nanoparticles (NPs), which face significant manufacturing and regulatory obstacles for clinical translation. Simplifying the genetic payload and improving plasmid characteristics are crucial for advancing these promising immunotherapies.

Researchers engineered novel bicistronic plasmids designed to co-express 4-1BBL and IL-12 from a single genetic construct. This co-expression was achieved using either a T2A peptide or a (G4S)5 linker to ensure coordinated protein production. To further enhance clinical viability, these constructs were integrated into smaller, antibiotic resistance-free NanoPlasmid™ backbones. The primary aim was to develop a more streamlined and compliant system for delivering these critical immunomodulators, addressing the complexities of manufacturing and regulatory approval inherent in dual-plasmid systems.

The study successfully developed and characterized bicistronic plasmid designs that efficiently co-express both 4-1BBL and IL-12 from a single genetic unit. By incorporating either a T2A peptide or a (G4S)5 linker, the team created robust constructs capable of simultaneous production of these key immunomodulatory proteins. This engineering feat directly addresses the logistical challenges of delivering multiple genetic components. Furthermore, the integration of these bicistronic designs into NanoPlasmid™ technology yielded smaller, antibiotic resistance-free plasmids. This advancement is critical for clinical translation, as NanoPlasmid™ backbones offer improved safety profiles and simplified manufacturing processes compared to traditional plasmid vectors. The successful development of these streamlined genetic tools lays a foundational step for more efficient and scalable production of 4-1BBL/IL-12-based immunotherapies. This approach significantly reduces the complexity associated with multi-plasmid systems, offering a clear path towards overcoming manufacturing and regulatory bottlenecks.

The engineering of bicistronic plasmids co-expressing 4-1BBL and IL-12 via T2A peptide or (G4S)5 linker and their integration into NanoPlasmid™ backbones represents a critical advancement for clinical translation.